Would you buy this? ACHV Look at the volume!

On July 31th : Achieve Life Sciences receives U.S. patent for its novel analogs of cytisinicline for use in prevention or treatment of CNS and addictive disorders.

Aimed at regaining compliance with Nasdaq's $1 minimum bid price listing requirement, Achieve Life Sciences has executed a 1:20 reverse split of its common stock.

Achieve Life Sciences is scheduled to be releasing its earnings data after the market closes on Thursday, August 6th. Analysts expect Achieve Life Sciences to post earnings of ($0.19) per share for the quarter.

If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.